NCT00701480

Brief Summary

Skin cleanser for daily used is essential and one of the most common questions asked by acne patients. There are studies reported beneficial effects of cleansers in acne treatment. Extracts of plants as active ingredients in skin cleansers are increasingly popular worldwide. Roselle is a common tropical shrub. Usually, the calyces of the plant have been used to make beverages but it also used in Thai traditional medicine for several purposes including as antiseptic and astringent. The extract of roselle showed antioxidant and keratolytic effects from previous studies which fit to the pathogenesis of acne. The aims of the study is to determine the safety and efficacy of skin cleanser contained roselle extract in acne.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Apr 2008

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

June 17, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 19, 2008

Completed
12 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2008

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2008

Completed
Last Updated

June 19, 2008

Status Verified

June 1, 2008

Enrollment Period

3 months

First QC Date

June 17, 2008

Last Update Submit

June 17, 2008

Conditions

Keywords

acneskin cleanserHibiscus sabdariffaRosellesafetyefficacy

Outcome Measures

Primary Outcomes (1)

  • 1. Safety evaluation: Patch test 2. Efficacy evaluation: Acne lesions counts/ acne severity grading

    6 weeks

Secondary Outcomes (1)

  • 1. Safety evaluation: "a." Skin properties by visual and tactile features., "b." Biophysical parameters of skin. 2.Efficacy evaluation: Patient assessments.

    6 weeks

Study Arms (2)

1

EXPERIMENTAL

skin cleanser contained Hibiscus sabdariffa

Other: skin cleanser contained Hibiscus sabdariffa extract

2

ACTIVE COMPARATOR

marketed skin cleanser

Other: marketed skin cleanser

Interventions

face washing 2-3 times/day

Also known as: Roselle skin cleanser
1

face washing 2-3 times/day

Also known as: Clean and Clear, Clearasil, Neutrogena
2

Eligibility Criteria

Age12 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • age 12-45 yrs,both sex
  • clinical diagnosis of mild to moderately severe acne vulgaris(grade 1-3)
  • have at least 10 facial acne lesions
  • not changing any acne treatment during study period
  • able to follow up according to protocol
  • Written informed consent

You may not qualify if:

  • pregnant or breast feeding
  • severe acne(grade4 or nodulocystic acne)
  • treated with isotretinoin orally during the last 3 months
  • have other systemic disease or illness
  • have allergic history to Roselle

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thammasat University

KlongLaung, Pathumtanee, 12120, Thailand

RECRUITING

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Benzoyl Peroxide

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

BenzoatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Mali - Achariyakul, MD.

    Thammasat University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mali - Achariyakul, MD.

CONTACT

Narumol - Teeranulak, MD.

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 17, 2008

First Posted

June 19, 2008

Study Start

April 1, 2008

Primary Completion

July 1, 2008

Study Completion

September 1, 2008

Last Updated

June 19, 2008

Record last verified: 2008-06

Locations